Paper Details

  1. Home
  2. Paper Details

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.

Author: CurranAdrián, MoltóJosé, Pérez-ValeroIgnacio

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Darunavir/cobicistat, a fixed-dose combination boosted protease inhibitor, showed comparable efficacy to ritonavir-boosted darunavir in treating HIV infection.
Paper Details　
Original Abstract of the Article :
Rezolsta® (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection. It contains darunavir, a protease inhibitor with a well-known safety and efficacy profile, and the new pharmacokinetic enhancer cobicistat. The conv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26035169

データ提供：米国国立医学図書館（NLM）

Rezolsta®: A New Era in HIV Treatment

[HIV infection] has become a manageable chronic condition thanks to advancements in antiretroviral therapy (ART). This study introduces [Rezolsta® (darunavir/cobicistat)], a new fixed-dose combination boosted protease inhibitor for the treatment of HIV infection. The researchers highlight the convenience and efficacy of this new therapeutic approach.

Rezolsta®: A Game-Changer for HIV Management

Rezolsta® offers several advantages over previous HIV treatment options, including a convenient fixed-dose combination, improved adherence due to simplified dosing, and comparable efficacy to other boosted protease inhibitors. The study demonstrates the potential of Rezolsta® to significantly improve the lives of individuals living with HIV by providing a more convenient and effective treatment option. This research represents a significant step forward in the ongoing fight against HIV infection.

Living with HIV: Empowering Individuals Through Access to Effective Treatment

HIV infection continues to be a significant global health concern, but with advancements in ART, individuals can live long, healthy lives. Rezolsta® offers a promising new treatment option that can help to improve adherence and overall well-being for people living with HIV. This research reinforces the importance of ongoing research and development to create better treatments and provide greater access to care for those affected by this complex condition.

Dr. Camel's Conclusion

The sands of time have witnessed countless advancements in the fight against HIV infection. Rezolsta® represents a milestone in this ongoing journey, offering a more convenient and effective treatment option for individuals living with this challenging condition. As a researcher, I am inspired by the relentless pursuit of better treatments, a pursuit that reflects humanity's enduring quest for health and well-being.
Date :
  1. Date Completed 2016-02-25
  2. Date Revised 2015-06-03
Further Info :

Pubmed ID

26035169

DOI: Digital Object Identifier

26035169

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.